Hepatitis C News and Research

Latest Hepatitis C News and Research

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

5 Apr 2011
Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

4 Apr 2011
Study demonstrates in vitro infection and HEV replication in human hepatocytes

Study demonstrates in vitro infection and HEV replication in human hepatocytes

4 Apr 2011
BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

4 Apr 2011
BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

4 Apr 2011
NAA joins with organizations worldwide to raise awareness about autism

NAA joins with organizations worldwide to raise awareness about autism

4 Apr 2011
New data: Quadruple therapy can effectively treat patients with HCV

New data: Quadruple therapy can effectively treat patients with HCV

4 Apr 2011
Entry inhibitors can provide first new hepatitis B & D treatments for many years

Entry inhibitors can provide first new hepatitis B & D treatments for many years

2 Apr 2011
Experts must monitor new antiviral compounds for HCV treatment

Experts must monitor new antiviral compounds for HCV treatment

2 Apr 2011
Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

2 Apr 2011
MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

2 Apr 2011
Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

2 Apr 2011
Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

2 Apr 2011
Series of new clinical trials confirm range of viable treatment options for HCV patients

Series of new clinical trials confirm range of viable treatment options for HCV patients

2 Apr 2011
Encouraging early data from HCV vaccine phase I trial presented at International Liver Congress

Encouraging early data from HCV vaccine phase I trial presented at International Liver Congress

2 Apr 2011
Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

1 Apr 2011
Biota receives US$231 million BARDA contract to advance laninamivir development

Biota receives US$231 million BARDA contract to advance laninamivir development

1 Apr 2011
Donation after cardiac death may broaden the scope of organ donor selection

Donation after cardiac death may broaden the scope of organ donor selection

1 Apr 2011
New findings from two modeling studies can help reduce HCV-related deaths in Europe

New findings from two modeling studies can help reduce HCV-related deaths in Europe

1 Apr 2011
Lymphocyte-hepatocyte interactions: Hepatitis C virus changes the rules

Lymphocyte-hepatocyte interactions: Hepatitis C virus changes the rules

1 Apr 2011

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback